Clinical Trials Logo

Filter by:
NCT ID: NCT02247245 Completed - Atrial Fibrillation Clinical Trials

The Influence of Heart Rate Limitation on Exercise Tolerance in Pacemaker Patients.

TREPPE
Start date: September 2014
Phase: N/A
Study type: Interventional

To examine the effects of heart rate reduction on exercise capacity in control subjects and patients with chronic heart failure.

NCT ID: NCT02247154 Completed - Clinical trials for Primary or Secondary Antibody Deficiency

A Study of the Safety and Efficacy of Vigam® Liquid in Patients With Primary or Secondary Antibody Deficiency

Start date: April 1999
Phase: Phase 4
Study type: Interventional

To determine: 1. The safety of Vigam® Liquid in patients with primary or secondary antibody deficiency (PAD or SAD). 2. The efficacy of Vigam® Liquid in patients with primary or secondary antibody deficiency. 3. The half-life of Vigam® Liquid after 4 months of treatment. 4. The subclass and total gammaglobulin concentrations after each infusion of Vigam® Liquid.

NCT ID: NCT02247141 Completed - Clinical trials for Primary Antibody Deficiency

A Multi-centre Open Study to Assess the Safety and Efficacy of Subgam®

Start date: June 2000
Phase: Phase 3
Study type: Interventional

The primary objective was to determine the efficacy of Human Normal Immunoglobulin (Subgam®) given subcutaneously by weekly infusion to patients with primary antibody deficiency. The secondary objective was to determine the safety of Subgam® given subcutaneously by weekly infusion to patients with primary antibody deficiency.

NCT ID: NCT02246998 Completed - HIV-1 Infection Clinical Trials

Renal Effect of Stribild or Other Tenofovir DF-containing Regimens Compared to Ritonavir-boosted Atazanavir Plus Abacavir/Lamivudine in Antiretroviral Treatment-naive HIV-1 Infected Adults

Start date: December 15, 2014
Phase: Phase 4
Study type: Interventional

The primary objective of this study is to assess glomerular function before and during administration of stribild (STB; elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate (E/C/F/TDF)) or a regimen containing TDF without cobicistat (COBI) as ritonavir (RTV)-boosted atazanavir (ATV/r) plus truvada (TVD; FTC/TDF) or atripla (ATR; efavirenz/emtricitabine/tenofovir disoproxil fumarate (EFV/FTC/TDF)) compared to a regimen containing neither TDF nor COBI as ATV/r plus abacavir/lamivudine (ABC/3TC) via determination of actual glomerular filtration rate (aGFR) using iohexol (a probe GFR marker) plasma clearance and estimated (calculated) glomerular filtration rate (eGFR).

NCT ID: NCT02246985 Completed - Clinical trials for Cardiovascular Disease

Bioavailability of Carotenoids Added Into Processed Foods

CAROTFoods
Start date: July 2014
Phase: N/A
Study type: Interventional

Carotenoids are a family of pigments found abundantly in fruits and vegetables. They are responsible for the colour of many fruits and vegetables such as tomatoes, melon, peppers and orange coloured fruits and vegetables. Carotenoids such as beta-carotene are important for the human body as precursors of vitamin A. They are also thought to be important as anti-oxidants and may help protect against cancer and heart disease. Although many foods are rich sources of carotenoids poor bioavailability often limits the amounts that are absorbed and available for metabolism in humans. Devising practical ways and means of increasing carotenoid bioavailability could lead to better health outcomes. Processed foods are now widely eaten by many, both for their taste and convenience. No studies have thus far looked at the bioavailability of carotenoids that have been added into processed foods. Thus the purpose of this study is to investigate the bioavailability of carotenoids that have been incorporated into processed food products (bread and mayonnaise).

NCT ID: NCT02246881 Completed - Clinical trials for Von Willebrand Disease

A Study to Compare the Pharmacokinetics and Safety of Current Factor VIII Concentrate and Optivate® in Haemophilia A.

Start date: October 2001
Phase: Phase 3
Study type: Interventional

The main objective of the study is to compare the pharmacokinetics of Optivate® with the subject's current FVIII concentrate when given as a bolus dose of 50IU/kg. The secondary objective is to compare the first and second pharmacokinetic assessments on Optivate® (and recovery if a subject changes batch) to evaluate Optivate® in terms of clinical tolerance and safety.

NCT ID: NCT02246868 Completed - Haemophilia A Clinical Trials

An Open Study to Investigate the Safety and Efficacy of Optivate® in Severe Haemophilia A Patients.

Start date: September 2001
Phase: Phase 3
Study type: Interventional

The main objectives of this study are to compare the first and second recovery assessments and recovery when a subject changed batch and to assess whether haemostasis was achieved with Optivate® when treating a bleed. The secondary objectives are to evaluate the clinical tolerance and safety of Optivate®.

NCT ID: NCT02246855 Completed - Healthy Clinical Trials

A Comparison of the Pharmacokinetics, Safety and Tolerance of Two Formulations of a Liquid IVIg in Healthy Volunteers

Start date: August 2004
Phase: Phase 1
Study type: Interventional

The main object of the study is to compare the AUC0-84, of a single intravenous infusion of Vigam® Liquid (infused at the licensed rate of up to 3mL/min) with Gammaplex® (infused at up to 3mL/min and up to 6mL/min).

NCT ID: NCT02246842 Completed - Healthy Clinical Trials

A Study Comparing the Pharmacokinetics and Tolerance of D-Gam® to Rhophylac® in Rh-D-negative Healthy Volunteers.

Start date: May 2004
Phase: Phase 1
Study type: Interventional

The primary objective of the study was to compare peak serum anti-D levels (Cmax) of BPL's D-Gam® 1500 IU to Rhophylac® 1500IU in RhD-negative healthy volunteers.

NCT ID: NCT02246543 Completed - Satiety Clinical Trials

Whey Protein Study - Identification of Sustainable Satiety

Start date: August 2013
Phase: N/A
Study type: Interventional

This study will have the primary aim to investigate within-day changes in appetite after consumption of high-protein (HP, 30% of calories) and normal, or low, protein (LP, 15% of calories) whey protein meal, in solid and liquid form, on appetite and ad libitum food intake. Secondary objective will be to assess the statistical relationship between plasma concentrations of gut hormones and visual analogue scales (subjective hunger and fullness) and transit time. In order to investigate the interaction of food structure and protein content on appetite, this requires, in practice, either a differing amount (g) or calorie (kJ) load as a function of energy density (defined as kJ/100g). Delivering the test meal as a solid and liquid form gives an easy solution to achieve this manipulation without compromising the nutritional profile. Following on from this decision, it is easier to produce different preloads using whey protein (rather than meat protein), since it is easily incorporated into test meals.